CD8A and neoplasm: Together, these data have suggested that combined therapy of B10G5 and ALT-803 cooperatively not only can improve the generally machinery responsiveness of CD8 T cells in sMIC+ tumor-bearing mice, but also can enhance antigen-specific effector CD8 T cell responses.